XKH 001
Alternative Names: Anti-IL-25 monoclonal antibody - Kanova Biopharmaceutical; XKH-001Latest Information Update: 18 Aug 2023
Price :
$50 *
At a glance
- Originator Kanova Biopharmaceutical
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Interleukin 17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hypersensitivity; Inflammation
Most Recent Events
- 15 Aug 2023 Kanova Biopharmaceutical plans phase-I/II trial for Asthma (In adults, In volunteers) in September 2023 (SC, injection) (NCT05991661)
- 15 Jun 2022 Phase-I clinical trials in Hypersensitivity (In volunteers) in China (SC) (NCT05128409)
- 15 Jun 2022 Phase-I clinical trials in Inflammation (In volunteers) in China (SC) (NCT05128409)